International Journal of Antimicrobial Agents
Volume 25, Issue 5 , Pages 409-413 , May 2005

Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model

  • Alexander A. Firsov

      Affiliations

    • Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, 11 Bolshaya Pirogovskaya Street, Moscow 119021, Russia
    • Corresponding Author InformationCorresponding author. Tel.: +7 95 708 3341; fax: +7 95 245 0295.
    • ,
  • Irene V. Alferova

      Affiliations

    • Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, 11 Bolshaya Pirogovskaya Street, Moscow 119021, Russia
    • ,
  • Maria V. Smirnova

      Affiliations

    • Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, 11 Bolshaya Pirogovskaya Street, Moscow 119021, Russia
    • ,
  • Irene Yu. Lubenko

      Affiliations

    • Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, 11 Bolshaya Pirogovskaya Street, Moscow 119021, Russia
    • Institute of Normal Physiology, Russian Academy of Medical Sciences, Moscow, Russia
    • ,
  • Yury A. Portnoy

      Affiliations

    • Department of Pharmacokinetics and Pharmacodynamics, Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, 11 Bolshaya Pirogovskaya Street, Moscow 119021, Russia
    • ,
  • Stephen H. Zinner

      Affiliations

    • Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, USA

Received 8 November 2004 ,Accepted 9 February 2005.

References 

  1. Gunderson SM, Hayes RA, Quinn JP, et al. In vitro pharmacodynamic activities of ABT-492, a novel quinolone, compared to those of levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother. 2004;48:203–208
  2. Gustavson L, Hosmane B, Schweitzer S, et al. Pharmacokinetics and safety of multiple oral doses of ABT492. In: Programme and abstracts of the forty-third interscience conference on antimicrobial agents and chemotherapy, San-Diego, CA, USA. Washington, DC, USA: American Society for Microbiology; 2003. p. 4 [abstract A-16].
  3. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet. 1997;32:101–119
  4. Firsov AA, Zinner SH. Use of modeling techniques to aid in antibiotic selection. Curr Infect Dis Rep. 2001;3:35–43
  5. Firsov AA, Vostrov SN, Lubenko IY, et al. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemother. 2004;54:178–186
  6. Zinner SH, Vostrov SN, Alferova IV, et al. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in-vitro dynamic model. Int J Antimicrob Agents. 2004;24:173–177
  7. Firsov AA, Shevchenko AA, Vostrov SN, et al. Inter- and intra-quinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrob Agents Chemother. 1998;42:659–665
  8. Firsov AA, Savarino D, Ruble M, et al. Predictors of effect of ampicillin-sulbactam against TEM-1 beta-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC. Antimicrob Agents Chemother. 1996;40:734–738
  9. Coyle EA, Kaatz GW, Rybak MJ. Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother. 2001;45:1654–1659
  10. Lister PD, Sanders CC. Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. J Antimicrob Chemother. 2001;47:811–818
  11. Hershberger E, Rybak MJ. Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model. Antimicrob Agents Chemother. 2000;44:598–601

PII: S0924-8579(05)00048-8

doi: 10.1016/j.ijantimicag.2005.02.004

International Journal of Antimicrobial Agents
Volume 25, Issue 5 , Pages 409-413 , May 2005

Article Tools

* Image Usage & Resolution